Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

neuroone medical technologies corp - NMTC

NMTC

Close Chg Chg %
1.62 0.07 4.32%

Pre-Market

1.69

+0.07 (4.32%)

Volume: 275.01K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Trade Now

Company Overview: neuroone medical technologies corp - NMTC

NMTC Key Data

Open

$1.68

 Day Range

1.58 - 1.73

52 Week Range

1.42 - 6.90

 Market Cap

$14.75M

Shares Outstanding

9.11M

 Public Float

7.20M

Beta

0.64

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.88

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

775.31K

  

NMTC Performance

1 Week
 
 4.32%
 
1 Month
 
 3.68%
 
3 Months
 
 -47.84%
 
1 Year
 
 -68.32%
 
5 Years
 
 -93.85%
 

NMTC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About neuroone medical technologies corp - NMTC

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in diagnostics, ablations, and deep brain stimulation technology for brain-related conditions. Its products include Evo Cortical, Evo sEEG, and OneRF. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

NMTC At a Glance

NeuroOne Medical Technologies Corp.
7599 Anagram Drive
Eden Prairie, Minnesota 55344
Phone 1-952-426-1383 Revenue 12.10M
Industry Medical Specialties Net Income -3,605,374.00
Sector Health Technology 2025 Sales Growth 250.353%
Fiscal Year-end 09 / 2026 Employees 18
View SEC Filings

NMTC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.949
Price to Book Ratio 6.283
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.409
Enterprise Value to Sales 2.428
Total Debt to Enterprise Value 0.009

NMTC Efficiency

Revenue/Employee 672,094.00
Income Per Employee -200,298.556
Receivables Turnover 9.565
Total Asset Turnover 1.489

NMTC Liquidity

Current Ratio 4.43
Quick Ratio 3.463
Cash Ratio 2.853

NMTC Profitability

Gross Margin 67.297
Operating Margin -34.936
Pretax Margin -29.802
Net Margin -29.802
Return on Assets -44.38
Return on Equity -91.338
Return on Total Capital -49.124
Return on Invested Capital -87.593

NMTC Capital Structure

Total Debt to Total Equity 3.772
Total Debt to Total Capital 3.635
Total Debt to Total Assets 2.453
Long-Term Debt to Equity 2.024
Long-Term Debt to Total Capital 1.95
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neuroone Medical Technologies Corp - NMTC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.12M 3.41M 3.45M 12.10M
Sales Growth
+772.60% +60.73% +1.33% +250.35%
Cost of Goods Sold (COGS) incl D&A
241.96K 1.50M 2.37M 3.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
226.21K 199.27K 246.79K 261.68K
Depreciation
203.90K 176.95K 224.48K 239.36K
Amortization of Intangibles
22.32K 22.32K 22.32K 22.32K
COGS Growth
-12.30% +518.24% +58.65% +66.70%
Gross Income
1.88M 1.91M 1.08M 8.14M
Gross Income Growth
+5,802.03% +1.79% -43.52% +654.07%
Gross Profit Margin
+88.59% +56.10% +31.27% +67.30%
2022 2023 2024 2025 5-year trend
SG&A Expense
11.25M 13.87M 12.97M 12.37M
Research & Development
4.93M 6.94M 5.07M 4.98M
Other SG&A
6.32M 6.93M 7.90M 7.38M
SGA Growth
+10.41% +23.31% -6.49% -4.62%
Other Operating Expense
- - - -
-
Unusual Expense
- 663.63K 327.09K (784.67K)
EBIT after Unusual Expense
(10.03M) (11.96M) (12.21M) (3.44M)
Non Operating Income/Expense
31.15K 95.76K 125.18K 170.49K
Non-Operating Interest Income
- - 31.00K 200.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 228.99K 334.06K
-
Interest Expense Growth
- - -100.00% +45.89%
-
Gross Interest Expense
- - 228.99K 334.06K
-
Interest Capitalized
- - - -
-
Pretax Income
(10.00M) (11.86M) (12.32M) (3.61M)
Pretax Income Growth
-0.52% -18.60% -3.87% +70.73%
Pretax Margin
-471.67% -348.03% -356.74% -29.80%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(10.00M) (11.86M) (12.32M) (3.61M)
Minority Interest Expense
- - - -
-
Net Income
(10.00M) (11.86M) (12.32M) (3.61M)
Net Income Growth
-0.52% -18.60% -3.87% +70.73%
Net Margin Growth
-471.67% -348.03% -356.74% -29.80%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(10.00M) (11.86M) (12.32M) (3.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(10.00M) (11.86M) (12.32M) (3.61M)
EPS (Basic)
-3.7502 -3.9268 -2.7617 -0.5387
EPS (Basic) Growth
+32.79% -4.71% +29.67% +80.49%
Basic Shares Outstanding
2.67M 3.02M 4.46M 6.69M
EPS (Diluted)
-3.7502 -3.9268 -2.7617 -0.5387
EPS (Diluted) Growth
+32.79% -4.71% +29.67% +80.49%
Diluted Shares Outstanding
2.67M 3.02M 4.46M 6.69M
EBITDA
(9.14M) (11.76M) (11.64M) (3.96M)
EBITDA Growth
+9.24% -28.61% +0.98% +65.94%
EBITDA Margin
-431.17% -344.99% -337.11% -32.77%

Snapshot

Average Recommendation BUY Average Target Price 9.933
Number of Ratings 3 Current Quarters Estimate -0.217
FY Report Date 09 / 2026 Current Year's Estimate -0.737
Last Quarter’s Earnings -0.23 Median PE on CY Estimate N/A
Year Ago Earnings -0.54 Next Fiscal Year Estimate -0.633
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.22 -0.17 -0.74 -0.63
High Estimates -0.19 -0.14 -0.39 -0.41
Low Estimate -0.26 -0.22 -0.94 -0.78
Coefficient of Variance -17.47 -25.64 -40.96 -31.03

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Neuroone Medical Technologies Corp - NMTC

Date Name Shares Transaction Value
Apr 8, 2026 Paul R. Buckman Director 178,733 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Paul R. Buckman Director 26,036 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Jason Mills Director 49,687 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Jason Mills Director 26,036 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Jeffrey S. Mathiesen Director 156,343 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Jeffrey S. Mathiesen Director 26,036 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Edward S. Andrle Director 133,932 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2026 Edward S. Andrle Director 26,036 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2026 David A. Rosa CEO and President; Director 1,080,132 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.78 per share 842,502.96
Apr 2, 2026 Steven Mertens Chief Technology Officer 152,141 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.78 per share 118,669.98
Apr 2, 2026 Mark Christanson Business Development Director 198,920 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.74 per share 147,200.80
Apr 2, 2026 Mark Christanson Business Development Director 198,667 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.78 per share 154,960.26

Neuroone Medical Technologies Corp in the News